Gordon R Julian

US Patent:

60018054, Dec 14, 1999

Filed:

Aug 12, 1996

Appl. No.:

8/689489

Inventors:

Jesse M. Jaynes - Raleigh NC
Gordon R. Julian - Cary NC

Assignee:

Demegen, Inc. - Pittsburgh PA

International Classification:

A01N 102
A61K 3810
A61K 3816
C12N 506

US Classification:

514 12

Abstract:

A method of treating a wound of a mammalian subject in need of such treatment, to promote healing thereof, comprising administering to the subject, e. g. , to the wound locus, a composition comprising a fibroblast and keratinocyte proliferatingly effective amount of an amphipathic peptide, preferably an amphipathic peptide which is antimicrobially effective at such locus. A method is also disclosed of stimulating the accelerated growth of dermal tissue in a tissue culture containing same, comprising applying to the tissue culture a fibroblast and keratinocyte proliferatingly effective amount of an amphipathic peptide, by which the dermal tissue may be grown to produce skin for skin grafting purposes, utilizing a dermal tissue culture containing dermal tissue material of a skin graft recipient of such skin. Novel amphipathic peptides suitable for use in such methods are disclosed.

US Patent:

57444455, Apr 28, 1998

Filed:

Jun 1, 1995

Appl. No.:

8/457798

Inventors:

Jesse M. Jaynes - Baton Rouge LA
Gordon R. Julian - Cary NC

Assignee:

Demeter Biotechnologies, Ltd. - Durham NC

International Classification:

A61K 3800
A61K 3810
A61K 3816

US Classification:

514 12

Abstract:

A method of treating pulmonary disease states, e. g. , a disease state selected from the group consisting of: cystic fibrosis, neoplasias, bronchogenic cancers, pneumonia, bronchitis, bronchopulmonary viral infections, and bronchopulmonary microbial infections, comprising delivery of an amphipathic non-naturally occurring peptide to an appropriate corporeal site, e. g. , pulmonary and/or gastrointestinal loci, to effectively treat such diseases. In a further specific aspect, the invention contemplates a method of treating cystic fibrosis by delivery of lytic, amphipathic non-naturally occurring peptides to pulmonary loci, thereby effecting treatment of bronchopulmonary microbial infections associated with cystic fibrosis through lysis of pathogenic bacteria. Peptides delivered to a gastrointestinal locus preferably are non-lytic, so as not to affect normal gastrointestinal flora, and preferably are chemically modified to confer enhanced proteolytic resistance for an oral method of delivery. Peptides delivered to a pulmonary locus advantageously exhibit lytic activity and do not require chemical modification for proteolytic resistance.

US Patent:

55611079, Oct 1, 1996

Filed:

Apr 20, 1994

Appl. No.:

8/231730

Inventors:

Jesse M. Jaynes - Raleigh NC
Gordon R. Julian - Cary NC

Assignee:

Demeter Biotechnologies, Ltd. - Durham NC

International Classification:

A61K 3810
A61K 3816
C07K 708
C07K 1400

US Classification:

514 12

Abstract:

A method of treating a wound of a mammalian subject in need of such treatment, to promote healing thereof, comprising administering to the subject, e. g. , to the wound locus, a composition comprising a fibroblast and keratinocyte proliferatingly effective amount of an amphipathic peptide, preferably an amphipathic peptide which is antimicrobially effective at such locus. A method is also disclosed of stimulating the accelerated growth of dermal tissue in a tissue culture containing same, comprising applying to the tissue culture a fibroblast and keratinocyte proliferatingly effective amount of an amphipathic peptide, by which the dermal tissue may be grown to produce skin for skin grafting purposes, utilizing a dermal tissue culture containing dermal tissue material of a skin graft recipient of such skin. Novel amphipathic peptides suitable for use in such methods are disclosed.

US Patent:

61911100, Feb 20, 2001

Filed:

Jan 19, 1999

Appl. No.:

9/232802

Inventors:

Jesse M. Jaynes - Raleigh NC
Gordon R. Julian - Cary NC

Assignee:

Demegen, Inc. - Pittsburgh PA

International Classification:

A61K 3810
A61K 3816
C07K 708
C07K 1400

US Classification:

514 12

Abstract:

A method of treating a wound of a mammalian subject in rneed of such treatment, to promote healing thereof, comprising administering to the subject, e. g. , to the wound locus, a composition comprising a fibroblast and keratinocyte proliferatingly effective amount of an amphipathic peptide, preferably an amphipathic peptide which is antimicrobially effective at such locus. A method is also disclosed of stimulating the accelerated growth of dermal tissue in a tissue culture containing same, comprising applying to the tissue culture a fibroblast and keratinocyte proliferatingly effective amount of an amphipathic peptide, by which the dermal tissue may be grown to produce skin for skin grafting purposes, utilizing a dermal tissue culture containing dermal tissue material of a skin graft recipient of such skin. Novel amphipathic peptides suitable for use in such methods are disclosed.

US Patent:

59689048, Oct 19, 1999

Filed:

Jun 7, 1995

Appl. No.:

8/475328

Inventors:

Gordon R. Julian - Bozeman MT
Jesse M. Jaynes - Raleigh NC

Assignee:

Demegen, Inc. - Pittsburgh PA

International Classification:

A61K 3810
A61K 3816
C07K 708
C07K 1400

US Classification:

514 12

Abstract:

A non-neurotoxin, arginine residue-containing non-naturally occurring lytic peptide comprising a sequence of amino acid residues in sufficient number and arrangement to confer lytic activity to the peptide, wherein the guanido groups of the arginine residues and the. alpha. -amino group of the N-terminal amino acid are sufficiently glyoxylated to impart enhanced tryptic, chymotryptic, and aminopeptidase digestion resistance to the peptide. The compositions of the invention are suitable for in vivo administration. A method of-making the same, to impart enhanced tryptic digestion resistance thereto, comprising glyoxylating the guanido groups of the arginine residues and the. alpha. -- amino group of the N-terminal amino acid with glyoxa containing buffer for sufficient time and at sufficient conditions to glyoxylate the side chain and. alpha. -amino groups to sufficient extent to confer enhanced proteolytic digestion resistance to the peptide.

US Patent:

57734135, Jun 30, 1998

Filed:

Jun 1, 1995

Appl. No.:

8/457171

Inventors:

Jesse M. Jaynes - Raleigh NC
Gordon R. Julian - Cary NC

Assignee:

Demeter Biotechnologies, Ltd. - Durham NC

International Classification:

A61K 3816
C07K 708
C07K 1400

US Classification:

514 12

Abstract:

A method of treating neoplasias, including female mammalian neoplasias such as breast, cervical, uterine, and ovarian neoplasias, as well as other neoplasias including prostatic, dermal, and bronchogenic cancers, comprising delivery of an effective non-naturally occurring, non-cytologically proliferative lytic peptide to an appropriate corporeal site to effectively treat such disease state. Particlularly preferred lytic peptide agents include small (23-39 amino acids) amphipathic cationic lytic peptides from the classes of synthetic analog derivatives of mellittin, cecropin, magainin, and defensin peptides, most preferably melittic and defensin peptides from the class of synthetic analogs of melittin, cecropin, maganin, and defensin peptides, most preferably synthetic analogs of melittic and defensin peptides.

US Patent:

57170649, Feb 10, 1998

Filed:

Apr 24, 1995

Appl. No.:

8/427001

Inventors:

Gordon R. Julian - Bozeman MT
Jesse M. Jaynes - Raleigh NC

Assignee:

Demeter Biotechnologies, Ltd. - Durham NC

International Classification:

C07K 500
C07K 700
C07K 1700
A61K 3800

US Classification:

530324

Abstract:

A tryptic digestion-resistant, non-naturally occurring lytic peptide comprising a sequence of amino acid residues containing mainly alanine, valine and lysine amino acid residues, wherein the. epsilon. -amino groups of the lysine residues and the. alpha. -amino group of the N-terminal amino acid are sufficiently methylated to impart enhanced tryptic, chymotryptic, and aminopeptidase digestion resistance to the peptide. The secondary conformation of the peptide is an ordered periodic structure such as an amphipathic. alpha. -helix or a. beta. -pleated sheet. The compositions of the invention are suitable for in vivo administration. A method of making the same, to impart enhanced tryptic digestion-resistance thereto, comprising reductively alkylating the. epsilon. -amino groups of the lysine residues and the. alpha. -amino group of the N-terminal amino acid with a methyl-providing reagent in the presence of an heterocyclic amine-borane reducing agent for sufficient time and at sufficient conditions to methylate the. alpha. -and. epsilon.